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Background: We aimed to describe orbital positron emission tomography/computed tomography (PET/CT)
imaging findings, both structural and metabolic, in different clinical stages of Graves ophthalmopathy (GO). This
prospective, observational, cross-sectional study examined 32 eyes of 16 patients with GO.
Methods: Patients were assessed with a complete ophthalmological evaluation and assigned a VISA classification
for GO. All patients underwent serum thyroid hormone measurement, antibody profile, and 18-fluorodeoxyglucose
positron emission tomography/computed tomography (18-FDG PET/CT) of the orbits. The 18-FDG uptake on PET
images was expressed in terms of maximum standard uptake value (SUVmax). CT images were analyzed, and orbital
structures were measured in millimeters. Vision, inflammation, strabismus, and overall appearance were assessed
according to the VISA classification system, thyroid hormone levels, antibody values, 18-FDG uptake, and thickness
of orbital structures.
Results: Altogether, 32 eyes of 16 patients (10 women, 6 men; mean age 44.31 ± 13 years, range 20–71 years) were
included. Three patients were hypothyroid, seven were euthyroid, and six were hyperthyroid. CT measurements of
extraocular muscle diameter were elevated (P < 0.05), and muscle 18-FDG uptake values were increased. Eyes with a
clinical VISA inflammation score of ≤ 4 had an average extraocular muscle SUVmax of 3.09, and those with a score
of ≥ 5 had an average SUVmax of 3.92 (P = 0.09), showing no clear correlation between clinically observed
inflammation and 18-FDG uptake. 18-FDG uptake values also did not show a correlation with extraocular muscle
diameter as measured by CT (R2 = 0.0755, P > 0.05).
Conclusions: We demonstrated a lack of correlation between 18-FDG extraocular muscle uptake and either clinical
inflammation score or muscle diameter. Although 18-FDG uptake has been used as an inflammation marker in
other pathologies, inflammation in GO may be clinically detected in PET/CT-negative cases, and cases with negative
clinical findings may show inflammation on PET/CT. Clinical evaluation is mandatory but may be insufficient and
inaccurate for classifying GO. A larger and homogeneous sample size and further research is needed to define the
role of PET/CT in detecting, grading, and follow-up of GO to optimize treatment of the inflammatory stage respect
clinical methods currently used.* Correspondence: drleogarciarojas@gmail.com
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Graves disease is one of the most common autoimmune
illnesses, with an annual incidence in women of 1 in 1000
[1]. In addition to thyroid involvement, ophthalmopathy
develops in 25% to 50% of patients [2]. The annual inci-
dence of Graves ophthalmopathy (GO) is 16 in every 100
000 women and 3 in every 100 000 men [3]. Approxi-
mately 5% of cases are severe, with chemosis, ptosis, and
visual disturbances [1].
Physiopathologic theories of the etiology of GO have
pointed to inflammation of the extraocular muscles and
connective tissue caused by immunoreactivity of the
thyroid-stimulating hormone (TSH) receptors [1,4]. In-
flammation and lymphocytic infiltration of fibroblasts
are thought to be caused by the presence of anti-TSH
receptor antibodies and anti-insulin growth factor recep-
tor 1 (IGF-1R) [1,5].
The expansion of the orbital tissues shifts the eyeball
forward, compromising venous outflow. These changes,
combined with local production of cytokines and other
inflammatory mediators, result in pain, proptosis, pe-
riorbital edema, conjunctival injection, and chemosis
[1]. The anatomical variability of the orbits and the
complex interaction of pathogenic mechanisms pose a
challenge to the construction of a reproducible classifi-
cation system to ensure prompt diagnosis, staging, and
treatment [6]. For this reason clinical diagnosis is often
augmented with imaging studies. Diagnostic imaging
methods such as CT show increased volume in the af-
fected extraocular muscles (EOMs) and in the orbital
fat, together or separately. It has been found that the
EOM findings usually develop somewhat later in the
course of the disease [1]. Assessment of the inflamma-
tory process that causes these abnormalities requires a
functional and structural study capable of detecting
early asymptomatic orbital abnormalities to provide
early treatment and limit the effects of GO [1].
New CT technology allows a detailed evaluation of
the orbit in less time, with fewer artifacts, subjecting the
patient to less radiation exposure, and with greater
spatial resolution [7]. Positron emission tomography
(PET) is a non-invasive diagnostic method that is used
in the diagnosis and staging of malignancies and is help-
ful in assessing some forms of inflammation [8]. PET al-
lows functional and metabolic assessment independent
of any structural alteration [7]. One of its main advan-
tages is its ability to detect early inflammation prior
to structural changes in the tissue [8]. 18-FDG is a
radiolabeled analogue to glucose that is used as a quan-
titative metabolic marker of glucose uptake, which
is often increased in malignancies and inflammation
[9,10]. Lymphocytes display high affinity for FDG [11–
13]. Glycolytic metabolism is elevated in oncologic and
inflammatory processes.The objective of this study was to describe imaging
findings, both structural and metabolic, by means of
PET/CT of patients with GO in different clinical stages.
Methods
This prospective, observational, cross-sectional study
was carried out in the Thyroid Clinic of the “Conde de
Valenciana” Ophthalmology Institute. The study was ap-
proved by the “Instituto de Oftalmología, Fundación
Conde de Valenciana, I.A.P,” and the “Unidad PET/CT
Ciclotrón, Universidad Nacional Autónoma de México”
Review Board and Ethics Committees and conducted
according the tenets of the Declaration of Helsinki. Each
subject gave informed consent. We included patients
18 years and older who suffered from GO with some de-
gree of clinical inflammatory activity. Patients either had
never been on anti-inflammatory treatment or radiation.
Patients underwent a complete ophthalmological evalu-
ation (visual acuity, color and binocular vision, ocular
adnexa, eye motility, surface and anterior segment bio-
microscopy and fundoscopy) and were assigned a VISA
classification [6]. Their serum thyroid hormones and
antibody profile were analyzed. 64-Slice CT was per-
formed with the Biograph TruePoint 64 PET-CT scanner
(Siemens Medical Solutions, Malvern, PA, USA). A total
of 555 MBq (15 mCi) of intravenous 18-FDG was ad-
ministered, and 2D images were acquired 90 minutes
after injection. A transmission CT scan was obtained to
correct emission images for photon attenuation. PET-
CT was prepared for acquisition and processing with a
spatial resolution of 2–5 mm (average 3 mm), with a
matrix acquisition of 256, 2.0 zoom, Gaussian filter,
FWHM 5.0, 6 iterations, 16 subset, and iterative recon-
struction. Orbital CT was acquired with the parameters
380 mAs and 120 kV and the reconstruction values of
Kernel H31s medium smooth, slice thickness 3 mm with
3 mm displacement for soft tissue evaluation, homoge-
neous b20f and b30f filters. Reconstruction of orbital
structures was from 0.75 to 1.0 mm. Axial, coronal, sa-
gittal, and volumetric images were generated.
Images were acquired with a protocol of minimal cere-
bral, visual, and ocular motility stimulation while the pa-
tient’s head was immobilized. The patients were instructed
to stare at a luminous stimulus.
PET images were analyzed in terms of maximum
standard uptake value (SUVmax), and structures on CT
images were analyzed and measured in millimeters. All
eyes were divided into two groups according to the VISA
classification of inflammation. The first group included
all eyes with an inflammation score of ≤ 4, and the sec-
ond group included all eyes with an inflammation score
of ≥ 5. These groups were compared with the SUVmax
measurements and analyzed to determine whether the
correlation of VISA score with SUVmax was significant.




Female, n (%) 10 (62.50)
Male, n (%) 6 (37.50)
Age (years) 44.31 ± 13 (20–71)
Time of diagnosis
Hyperthyroidism 109 (4–420)
Graves ophthalmopathy 63 (0–420)
Smoking
Never, n (%) 11 (68.75)
Former, n (%) 3 (18.75)
Active, n (%) 2 (12.50)
131I therapy
Previous, n (%) 9 (56.25)
Never, n (%) 7 (43.75)
Thyroid hormonal status
Hypothyroid, n (%) 3 (18.75)
Euthyroid, n (%) 7 (43.75)
Hyperthyroid, n (%) 6 (37.50)
Table 3 Muscle/ON/SOV thickness values on CT and
uptake on PET
Structure CT (mm) PET (SUVmax)
Average ± 2 SD Range Average ± 2 SD Range
MR 4.45 ± 1.74 2.4-9.5 3.52 ± 1.44 2.07-4.96
SR 5.07 ± 1.94 2.6-10 3.36 ± 1.23 2.13-4.59
LR 3.44 ± 0.93\ 2-5.9 3.04 ± 1.55 1.49-4.58
IR 5.13 ± 1.72 2-9.5 3.50 ± 1.71 1.80-5.21
SO 3.11 ± 0.85 2-5.5 3.63 ± 1.23 2.40-4.86
IO 4.10 ± 1.26 2.6-6.8 2.59 ± 1.48 1.11-4.08
ON 4.08 ± 0.93 2.4-6.5 1.62 ± 0.48 1.14-2.10
SOV 1.96 ± 0.59 1-3.1 0 0
CT Computed Tomography, PET Positron Emission Tomography,
SD Standard Deviation, mm millimeters, SUVmax maximum Standardized
Uptake Value, MR Medial Rectus, SR Superior Rectus, LR Lateral Rectus,
IR Inferior Rectus, SO Superior Oblique, IO Inferior Oblique, ON Optic Nerve,
SOV Superior Ophthalmic Vein.
Table 4 Maximum uptake and thickness values of
extraocular muscles
Patient FDG uptake Thickness
on PET (SUVmax) on CT (mm)
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SD. Statistical analysis was performed with Student’s t test
to compare differences between groups. The relation
was calculated using Pearson’s correlation. A P value of
less than 0.05 was considered statistically significant. All
statistics in the present study were done using SPSS for
Windows (SPSS version 17.0, Chicago, IL).Table 2 VISA clinical characteristics
Vision (optic neuropathy)
Present n (%) 10 (31.25)
Absent n (%) 22 (68.75)
Inflammation (VISA scale) 3.43 ± 2.01 SD
0 Points, n (%) 0 (0)
1-4 Points, n (%) 21 (65.62)
5-8 Points, n (%) 11 (34.37)
Strabismus, diplopia, and restriction (0 a 3) 0.81 ± 1.06 SD
Binocular diplopia, n (%) 7 (43.75)
Restriction of eye movements, n (%) 14 (43.75)
Appearance
Mild, n (%) 11 (34.37)
Moderate, n (%) 18 (56.25)
Severe, n (%) 3 (9.37)Results
We included 32 eyes of 16 patients (10 women, 6 men)
with a mean age of 44.31 ± 13 years (range 20–71 years).
The mean time since the diagnosis of hyperthyroid-
ism was 109 months (range 4–420 months) and since
the diagnosis of GO was 63 months (0–420 months). Of
the 16 patients, two were active smokers, three had
suspended tobacco smoking after hyperthyroidism diag-
nosis, and 11 denied smoking. Nine of the patients had
















FDG 18 F-fluorodeoxyglucose, PET Positron Emission Tomography,
SUVmax maximum Standardized Uptake Value, mm millimeters.
Table 5 Correlation between inflammation VISA score
and average FDG uptake by PET
Inflammation index (VISA) Averaged SUVmax SD N
≤ 4 3.09 1.13 21
≥ 5 3.92 1.52 11
FDG 18 F-fluorodeoxyglucose, PET Positron Emission Tomography,
SUVmax maximum Standardized Uptake Value, SD Standard Deviation.
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Six of these were treated with methimazole, two with
propranolol, and five with levothyroxine. No patients
had been treated with anti-inflammatory therapy in the
past six months. No patients had been treated with ra-
diation. Three patients were hypothyroid, seven were
euthyroid, and six were hyperthyroid despite treatment
at the time of the study (Table 1).Thyroid status
Serum levels of thyroid hormones ranged widely from
normal. The reference values were as follows: T3: 80–
220 ng/dL; T4 (thyroxine) 4.5–12.5 mg/dL; TSH 0.4–
6.0 U/dL; anti-thyroglobulin antibodies < 150 IU/mL;
anti-microsomal antibodies: < 75 IU/mL. The patients’
values were as follows: T3 1.83–467.28 ng/dL; T4 0.99–
28.5 mg/dL; TSH 0.02–45.66 U/dL. Two patients had
positive anti-thyroglobulin antibody results (> 150 IU/mL),
and five patients had positive anti-microsomal antibodies
(> 75 IU/mL).Ophthalmologic evaluation
The results of the CO-tailored ophthalmologic history
and physical examination were divided into four sub-
groups, according to the VISA classification.Figure 1 PET-CT correlation. PET values showed no correlation with CT meVision
Most patients had a good corrected visual acuity close to
20/20 (mean 20/22.65, range 20/20 to 20/40) with the
Snellen letter chart, 0.054 mean logMAR value. Ten eyes
had some degree of dyschromatopsia evaluated with the
Ishihara chart. No eye showed afferent pupillary defect
or optic disc hyperemia.
Inflammation
In all, 18 eyes were affected by retro-ocular pain; 21 ex-
perienced morning eyelid edema; 15 showed some de-
gree of chemosis; 27 had conjunctival injection; 18 had
palpebral injection; 21 had eyelid edema; and 5 had car-
uncular edema (this variable is not included in the VISA
classification).
Strabismus
Seven patients suffered from binocular diplopia. Seven
patients exhibited compensatory head positioning, and
14 eyes displayed restriction of movements.
Appearance
Appearance was evaluated through variables described in
the VISA classification and evaluation sheet. It was graded
as mild, moderate, or severe. Altogether, 11 eyes were
graded mild, 18 moderate, and 3 severe. The exoph-
thalmometry measurements were 17–27 mm in women
and 17–23 mm in men.
The comprehensive score of the four components of
the VISA classification yielded the following results: 10
eyes had some degree of dyschromatopsia. Twenty-one
eyes had a score between 1 and 4, and eleven eyes had a
score between 5 and 8. Seven patients presented with
diplopia, and fourteen eyes showed some restrictions ofasurements according to Pearson correlation results (R2 = 0.0755, P> 0.05).
Figure 2 The thickening of extraocular muscles was evaluated on multislice CT with volumetric reconstruction of a coronal slice. Left:
thickening is evident in the inferior, medial, and superior rectus muscles. Right: thickening of the four rectus muscles and SO.
Figure 3 Increased FDG uptake by the inferior and medial
rectus muscles on PET/CT.
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0.81 ± 1.06 (range 0–3) in the case of diplopia and re-
striction of eye movements (Table 2).
Computed tomography
The extraocular muscle thickness, optic nerve, and su-
perior ophthalmic vein were measured at their max-
imum diameter in the coronal plane. The medial rectus
(MR) thickness range was 2.4–9.5 mm; the superior
rectus (SR) 2.6–10.0 mm; the lateral rectus (LR) 2.0–
5.9 mm; the inferior rectus (IR) 2.0–9.5 mm; the super-
ior oblique (SO) 2.0–5.5 mm; the inferior oblique (IO)
2.6–6.8 mm; the optic nerve (ON) 2.4–6.5 mm; and the
superior ophthalmic vein (SOV) 1.0–3.1 mm (Table 3).
Positron emission tomography
The MR SUVmax range was 1.0–7.5; the SR 1.3–5.8; the
LR 0.9–6.7; the IR 1.1–8.2; the SO 1.6–6.1; the IO 1.3–
5.8; and the ON 1.0–3.1 (Table 3).
The patient with the greatest uptake in the EOMs had
a mean SUVmax value of 6.71. This correlated with the
thickest average measurement obtained by CT, with a
mean value of 5.01 mm. A similar condition occurred in
another patient, whose values were 4.20 SUVmax and
4.19 mm, respectively. This relationship prevailed in only
these two patients; the rest had no correlation between
uptake and muscle thickness values (R2 = 0.0755, P >
0.05) (Table 4).
PET correlation and clinical inflammation by means of
VISA
All eyes were divided into two groups according to the
degree of clinical inflammation assigned by the VISA
classification. The first group included all eyes with an
inflammation score of ≤ 4, and the second group in-
cluded all eyes with an inflammation score of ≥ 5. These
groups were evaluated according the mean value of FDG
uptake of EOMs on PET and compared to determinewhether the difference in the value of FDG uptake was
statistically significant. The first group had a mean
SUVmax of 3.09, and the second had a value of 3.92 (P =
0.09, power 3.91) (Table 5).
PET/CT correlation
There was no statistical correlation of SUVmax with CT
measurements in the scatterplot when Pearson’s correl-
ation was calculated (R2 = 0.0755, P > 0.05) (Figure 1).
Discussion
In 2006, Kuo et al [14] were the first to describe a PET/
CT study in a patient with GO. In this case, the detec-
tion of inflammation by FDG uptake was demonstrable
by this quantitative imaging method. In this study we
screened 16 patients (32 eyes) with a GO diagnosis, with
a predominance of females (ratio 1.0:0.6) with a wide
range of hormone levels.
No patient had a visual acuity lower than 20/40. However,
10 of 32 eyes showed some degree of dyschromatopsia.
None presented with an afferent pupillary defect or alter-
ations in the color of the papilla.
Inflammation is one of the most difficult variables to
identify clinically due to the variability of its manifestations
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as noninflammatory fibrosis, in the disorder. Among the
signs of inflammation in this study, conjunctival injection
was the most common, followed by eyelid edema. Carun-
cular edema (a sign not included in the VISA classi-
fication) was the least frequent. Strabismus was more
common than expected. Seven patients showed some de-
gree of binocular diplopia, which made them adopt a
compensatory head position, and 14 eyes had some re-
striction of eye movements. In terms of overall appear-
ance, 18 eyes showed a moderate degree of abnormality.
In 2007, Lerdlum et al [15] described the thickness of
the extraocular muscles in a population of 200 people by
means of CT, reporting the following average values and
ranges: 3.7 mm (2.8–4.6 mm) for the MR, 3.6 mm (2.4–
4.8 mm ) for the LR, 3.8 mm (2.4–5.3 mm) for the super-
ior complex (SC), and 4 mm (2.6–5.4 mm) for the IR.
Other authors, such as Lee, Ozgene, and Nugent [16–18]
have reported similar values. In this study, thickness aver-
aged higher than that reported in healthy subjects:
4.45 mm (2.4–9.5 mm) for MR, 3.44 mm (2–5.9 mm) for
the LR, 5.07 mm (2.6–10 mm) for the SR, and 5.13 mm
(2.0–9.5 mm) for IR. The difference between the thickness
of rectus EOMs in healthy individuals according to
Lerdlum et al [15],. compared with patients with GO who
participated in this study, was statistically significant (P <
0.05) in the case of MR, SR/SC, and IR but not for the LR.
This is a finding that matches the frequency of involve-
ment of the extraocular muscles in GO according to previ-
ous reports [19] (Figure 2, Table 3).
PET/CT showed increased FDG uptake in the MR and
IR (SUVmax 3.52 and 3.50, respectively) (Figure 3), which
are muscles that are usually thicker in patients with GO
[19]. This relationship suggests a difference in timing of
the diagnosis, where inflammation precedes muscle thick-
ening and fibrosis. An interesting finding is that the SO
muscle showed greater uptake than the rest of the mus-
cles, with an SUVmax of 3.63. This does not correlate with
the increased muscle thickness in the CT evaluation.
We did not observe a statistically significant differ-
ence (P = 0.09) in the degree of inflammation assessed
clinically by means of the VISA classification and
FDG-PET, although the power and the size of the sam-
ple in this study is not enough to conclude that there
is zero correlation.
There is no gold standard for detecting active inflam-
mation in GO, and VISA is insufficient for this purpose.
This suggests that 18-FDG may detect those cases in
which clinical assessment is confusing and VISA is not
precise. As previously published by our group [20], pa-
tients with GO do have increased FDG uptake compared
with patients without GO.
Despite the fact that muscular thickness values were
equally high in two of the three patients with the highestFDG uptake (Table 4), the PET/CT results showed no
correlation (R2 = 0.0755, P > 0.05), which suggests that
the morphological changes are completely independent
of the degree of inflammatory activity. Morphological
study is useful for evaluating orbital anatomy, but
according to our study it may not determine the inflam-
matory status of the orbital structures.
This study suggests that FDG-PET/CT may be a useful
tool for detecting inflammation in GO. The lack of a
gold standard tool to detect active inflammation makes
it difficult to compare this method and show a statistical
difference. VISA may detect inflammation in some cases,
but there may be a portion of patients that cannot be
correctly diagnosed. It is here that PET/CT may be use-
ful. 18-FDG PET/CT is possibly superior to other im-
aging studies such as CT alone and even magnetic
resonance imaging for detecting active inflammation, as
previous studies have reported in other structures [21].
It may be useful for assessing the inflammatory status
when clinical doubt exists.
The limitations of this study are the small sample, the
different times of onset of the hyperthyroidism and
ophthalmopathy, and the differences of hormonal status
among the patients.
In conclusion, GO is a pathological entity whose eti-
ology, pathophysiology, epidemiology, clinical assess-
ment, diagnosis, and treatment are under investigation.
None of the above aspects has been clarified and under-
stood entirely. Currently, there is no accurate, objective
tool for its clinical evaluation and for differentiating ac-
tive inflammatory states from fibrosis. The study of GO
by PET/CT provides valuable and useful information for
diagnosis, characterization, and therapy in cases where
clinical doubt exists. Further research is required to de-
fine the role of FDG-PET/CT in the detection, clinical
correlation, classification, and monitoring of GO.
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